Literature DB >> 24149602

The effect of tapering period on plasma pro-inflammatory cytokine levels and performance in elite male cyclists.

Negin Farhangimaleki1, Farzad Zehsaz, Peter M Tiidus.   

Abstract

The aim of this study was to investigate the effect of two different tapering period lengths on the concentration of plasma interleukin- 6 (IL-6), interleukin (IL-1β) and tumor necrosis factor-α (TNF-α) and performance in elite male cyclists. To this end, after completing 8 weeks progressive endurance exercise, twenty four high-level endurance cyclists were randomly assigned to one of two groups: a control group of cyclists (n = 12) continued performing progressive weekly training volume for 3 weeks while a taper group of cyclists (n = 12) proceeded with a 50% reduction in weekly training volume relative to the control group. A simulated 40 min time trial (40TT) performance ride was used as the criterion index of performance before and after the tapering period to evaluate the physiological and performance effects of each protocol. Blood samples were collected immediately post-40TT from all participants at the beginning of week 1, and the end of weeks 4, 8, 9 and 11. IL-1β, IL-6 and TNFα were assayed using a standard commercial ELISA kits (Quantikine; R & D Systems, Minneapolis, MN). The mean time to complete the 40TT in the taper group decreased significantly (p < 0.01) after both 1 and 3 weeks with reduced training volume relative to the control group. There were significant reductions in (p < 0.001) IL-1β, IL-6 and TNFα concentrations in the taper group relative to the control group at the end of the 3 week tapering period, but not at the end of the 1 week tapering period. These results demonstrate that both a 1 and a 3 week taper period will result in improved physical performance in trained cyclists but only a 3 week taper period will result in attenuation of post-exercise pro- inflammatory cytokines when compared to those continuing a more intense training regimen. Key pointsThe excessive endurance exercise-induced elevations in pro-inflammatory cytokines would, in turn, stimulate the release of anti-inflammatory cytokines.Elevations in pro-inflammatory cytokines indicate athletes are highly susceptible to infections.1and 3-week taper periods will reduce circulating pro-inflammatory cytokine levels thereby possibly limiting the chances of infection and potentially reducing the effects of these cytokines in inducing fatigue-like symptoms in athletes.

Entities:  

Keywords:  Endurance training; Tumor necrosis factor α.; immune; interleukin-1β; interleukin-6; performance

Year:  2009        PMID: 24149602      PMCID: PMC3761545     

Source DB:  PubMed          Journal:  J Sports Sci Med        ISSN: 1303-2968            Impact factor:   2.988


  29 in total

1.  Impact of three different types of exercise on components of the inflammatory response.

Authors:  I K Brenner; V M Natale; P Vasiliou; A I Moldoveanu; P N Shek; R J Shephard
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1999-10

2.  Changes in neutrophil surface receptor expression, degranulation, and respiratory burst activity after moderate- and high-intensity exercise.

Authors:  Jonathan Peake; Gary Wilson; Matthew Hordern; Katsuhiko Suzuki; Kanemitsu Yamaya; Kazunori Nosaka; Laurel Mackinnon; Jeff S Coombes
Journal:  J Appl Physiol (1985)       Date:  2004-04-09

3.  Aerobic and anaerobic profiles, heart rate and match analysis in older soccer players.

Authors:  Antonio Tessitore; Romain Meeusen; Monica Tiberi; Cristina Cortis; Rita Pagano; Laura Capranica
Journal:  Ergonomics       Date:  2005 Sep 15-Nov 15       Impact factor: 2.778

4.  Deleterious effects of short-term, high-intensity exercise on immune function: evidence from leucocyte mitochondrial alterations and apoptosis.

Authors:  T-C Tuan; T-G Hsu; M-C Fong; C-F Hsu; K K C Tsai; C-Y Lee; C-W Kong
Journal:  Br J Sports Med       Date:  2007-05-15       Impact factor: 13.800

5.  Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation.

Authors:  Peter Plomgaard; Karim Bouzakri; Rikke Krogh-Madsen; Bettina Mittendorfer; Juleen R Zierath; Bente K Pedersen
Journal:  Diabetes       Date:  2005-10       Impact factor: 9.461

6.  Mild endotoxaemia and the inflammatory response induced by a marathon race.

Authors:  G Camus; J Poortmans; M Nys; G Deby-Dupont; J Duchateau; C Deby; M Lamy
Journal:  Clin Sci (Lond)       Date:  1997-04       Impact factor: 6.124

7.  Elderly humans show prolonged in vivo inflammatory activity during pneumococcal infections.

Authors:  H Bruunsgaard; P Skinhøj; J Qvist; B K Pedersen
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

8.  The effects of taper on performance in distance runners.

Authors:  J A Houmard; B K Scott; C L Justice; T C Chenier
Journal:  Med Sci Sports Exerc       Date:  1994-05       Impact factor: 5.411

Review 9.  Exercise, nutrition and immune function.

Authors:  Michael Gleeson; David C Nieman; Bente K Pedersen
Journal:  J Sports Sci       Date:  2004-01       Impact factor: 3.337

10.  Using an interleukin-6 challenge to evaluate neuropsychological performance in chronic fatigue syndrome.

Authors:  M C Arnold; D A Papanicolaou; J A O'Grady; A Lotsikas; J K Dale; S E Straus; J Grafman
Journal:  Psychol Med       Date:  2002-08       Impact factor: 7.723

View more
  2 in total

1.  Effect of Acute and Chronic Aerobic Exercise on Immunological Markers: A Systematic Review.

Authors:  Ciro Alexandre Mercês Gonçalves; Paulo Moreira Silva Dantas; Isis Kelly Dos Santos; Matheus Dantas; Daliana Caldas Pessoa da Silva; Breno Guilherme de Araújo Tinoco Cabral; Ricardo Oliveira Guerra; Geraldo Barroso Cavalcanti Júnior
Journal:  Front Physiol       Date:  2020-01-24       Impact factor: 4.566

2.  The effect of aerobic exercise on immune biomarkers and symptoms severity and progression in patients with COVID-19: A randomized control trial.

Authors:  Ayman A Mohamed; Motaz Alawna
Journal:  J Bodyw Mov Ther       Date:  2021-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.